CCL5 is under a phase 1 clinical trial for autoimmune diabetes, while ST14, found in the minimal gene signature analysis, is patented-recorded and whose proposed functions include an important role in breast cancer invasion and metastasis according to the TTD database. Here, CCL5 is linked to breast cancer.